Company GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 12:14:03 14/05/2026 +04			5-day change	1st Jan Change
1,876.00 ^GBX	-0.53%		+0.78%	+2.66%

09:24am	UK Stocks-Factors to watch on May 14	RE
05-12	European Equities Traded in the US as American Depositary Receipts Decline Sharply in Tuesday Trading	MT

Business description: GSK plc

GSK plc is a United Kingdom-based biopharma company. The Companyâ€™s segments include Commercial Operations and Research and Development. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) with antibiotics. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development. The Company also engaged in ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody. The Company also owns HS235, a potential molecule for the treatment of pulmonary hypertension (PH).

Number of employees: 66,841

Sales by Activity: GSK plc

Fiscal Period: December	2021 (GBP)	2022 (GBP)	2023 (GBP)	2024 (GBP)	2025 (GBP)
Commercial Operations	-	29.32B	30.33B	31.38B	32.67B
Consumer Healthcare	9.61B	-	-	-	-
Vaccines	6.78B	-	-	-	-
Pharmaceuticals	17.73B	-	-	-	-

See all business segments

Geographical breakdown of sales: GSK plc

Fiscal Period: December	2021 (GBP)	2022 (GBP)	2023 (GBP)	2024 (GBP)	2025 (GBP)
United States (US)	15.09B	14.54B	15.82B	16.38B	16.86B
Rest of World	18.05B	14.09B	13.82B	14.28B	8.28B
Europe	-	-	-	-	6.85B
United Kingdom (UK)	975M	695M	693M	708M	683M

See all geographic segments

Executive Committee: GSK plc

Manager	Title	Age	Since
Luke Miels CEO	Chief Executive Officer	-	01/01/2026
Julie Brown DFI	Director of Finance/CFO	64	01/05/2023
Shobie Ramakrishnan CTO	Chief Tech/Sci/R&D Officer	-	01/12/2021
James Ford CMP	Compliance Officer	-	01/08/2018
Tony Wood CTO	Chief Tech/Sci/R&D Officer	-	19/01/2022

See GSK PLC governance

Composition of the Board of Directors: GSK plc

Director	Title	Age	Since
Luke Miels BRD	Director/Board Member	-	06/05/2026
Hal Barron BRD	Director/Board Member	64	01/01/2018
Jonathan Symonds CHM	Chairman	68	01/09/2019
Charles Bancroft BRD	Director/Board Member	66	01/05/2020
Anne Beal BRD	Director/Board Member	63	06/05/2021
Harry Dietz BRD	Director/Board Member	68	01/01/2022
Vishal Sikka BRD	Director/Board Member	59	18/07/2022
Elizabeth Anderson BRD	Director/Board Member	68	01/09/2022
Julie Brown BRD	Director/Board Member	64	01/05/2023
Wendy Becker BRD	Director/Board Member	60	01/10/2023

Composition of the Board of Directors

Shareholders: GSK plc

Name	Equities	%	Valuation
The Vanguard Group, Inc. 2.793 %	113,232,726	2.793 %	2 967 M p
Dodge & Cox 2.194 %	88,958,040	2.194 %	2 331 M p
BlackRock Investment Management (UK) Ltd. 1.778 %	72,082,936	1.778 %	1 889 M p
Schroder Investment Management Ltd. 1.7 %	68,950,767	1.7 %	1 807 M p
BlackRock Advisors (UK) Ltd. 1.59 %	64,468,557	1.59 %	1 689 M p

Name	Equities	%	Valuation
Dodge & Cox 3.38 %	68,517,969	3.38 %	3 584 M p
Fidelity Management & Research Co. LLC 3.328 %	67,469,409	3.328 %	3 529 M p
Dodge & Cox 2.746 %	55,669,429	2.746 %	2 912 M p
Fisher Asset Management LLC 1.703 %	34,522,363	1.703 %	1 806 M p
PRIMECAP Management Co. 1.243 %	25,204,538	1.243 %	1 318 M p

List of GSK PLC shareholders

Holdings: GSK plc

Name	Equities	%	Valuation
GLAXOSMITHKLINE PHARMACEUTICALS LIMITED 75%	127,054,524	75%	3 127 M $
GLAXOSMITHKLINE PAKISTAN LIMITED 82.59%	263,029,794	82.59%	322 M $
HALEON PAKISTAN LIMITED 85.79%	100,423,259	85.79%	265 M $
CRISPR THERAPEUTICS AG 3.34%	3,220,627	3.34%	169 M $
WAVE LIFE SCIENCES LTD. 9.48%	18,245,691	9.48%	129 M $
BIONTECH SE 0.37%	889,824	0.37%	92 M $
VIR BIOTECHNOLOGY, INC. 5.3%	8,550,954	5.3%	87 M $
IDEAYA BIOSCIENCES, INC. 1.52%	1,333,333	1.52%	39 M $
LYELL IMMUNOPHARMA, INC. 6.48%	1,512,659	6.48%	30 M $
DONG-A SOCIO HOLDINGS CO., LTD. 6.46%	434,642	6.46%	29 M $

Company details: GSK plc

GSK Plc

79 New Oxford Street

WC1A 1DG, London

+44 20 8047 5000

http://www.gsk.com

Group companies: GSK plc

Name	Category and Sector
GlaxoSmithKline IHC Ltd. GlaxoSmithKline IHC Ltd. Regional BanksFinance Provides banking services	Regional Banks
GlaxoSmithKline Ltd. GlaxoSmithKline Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline Ltd. is a company based in Hong Kong, Hong Kong.	Pharmaceuticals: Major
GlaxoSmithKline Ltd. GlaxoSmithKline Ltd. Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline Ltd. is a company based in Hong Kong, Hong Kong.	Pharmaceuticals: Major
Corixa Corp. Corixa Corp. BiotechnologyHealth Technology Develops and manufactures oncology and immunology products	Biotechnology
Corixa Corp. Corixa Corp. BiotechnologyHealth Technology Develops and manufactures oncology and immunology products	Biotechnology

See all subsidiaries

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GSK PLC	-0.53%	+0.78%	+37.72%	+27.45%	102B
ELI LILLY AND COMPANY	+2.61%	+2.91%	+36.15%	+133.81%	906B
JOHNSON & JOHNSON	+2.75%	+2.58%	+55.23%	+43.31%	555B
ABBVIE INC.	+0.31%	+1.69%	+10.90%	+41.69%	368B
ROCHE HOLDING AG	-0.94%	-2.05%	+21.74%	+10.73%	326B
ASTRAZENECA PLC	+0.45%	+3.79%	+37.88%	+15.15%	289B
NOVARTIS AG	+0.78%	+1.00%	+29.63%	+26.23%	285B
MERCK & CO., INC.	+0.96%	-0.10%	+48.05%	-3.15%	280B
NOVO NORDISK A/S	+0.91%	+2.12%	-31.78%	-49.10%	208B
AMGEN INC.	+0.05%	+1.61%	+24.40%	+44.43%	182B
Average	+0.51%	+1.03%	+26.99%	+29.06%	350.02B
Weighted average by Cap.	+0.69%	+1.23%	+31.14%	+50.20%